The health and safety of our patients, families and staff is our highest priority. Due to the COVID-19 pandemic, the Commonwealth of Massachusetts is requiring hospitals to meet established criteria as part of the state’s reopening plan. The Boston Shriners Hospital completed its Phase 1 attestation on May 27, 2020, and its Phase 2 attestation on June 15, 2020 and its Phase 3 attestation on July 13, 2020. The Phase 3 attestation was resubmitted and reaffirmed on November 16, 2020. The Boston Shriners Hospital also completed and submitted the state’s resurgence attestation on November 16, 2020.

If your child has an upcoming appointment, please contact your local Shriners Hospitals for Children location.

Shriners Hospitals for Children — Boston visitor information.

Skip to navigation

Mikhail Papisov, Ph.D.

Mikhail Papisov, Ph.D., is on the scientific staff at Shriners Hospitals for Children — Boston. He is an associate professor at Harvard Medical School and an investigator at Massachusetts General Hospital, Department of Radiology and Department of Surgery.

Dr. Papisov conducts basic and translational research, including collaborative studies of new pediatric therapeutics for children with the biotech and pharmaceutical industry. The data obtained by his laboratory provided guidance for clinical development of several biopharmaceuticals alleviating inherited enzyme deficiencies in children, including Replagal®. Dr Papisov’s focus of research includes investigation of poorly understood mechanisms of drug transport, in injury, in the organism and development of new therapeutics based on the discovered mechanisms of transport. Technologies developed by the laboratory have been transferred to the pharmaceutical industry and used in novel experimental therapeutics that are presently in clinical trials. His laboratory also provides preclinical PET/CT imaging and other support to other research groups of the hospital for studies of burn injury and metabolism.

Dr. Papisov has published over 60 publications and has given over 150 presentations at international and national scientific conferences. He has 18 issued U.S. patents and over 120 associated national patents worldwide. Dr. Papisov is the Scientific Founder of Mersana Therapeutics. He has multiple research grants from NIH, DoD, DoE, private foundations and the pharmaceutical industry (1996-2017); a major equipment grant in 2011; and presently has three active NIH grants.

Dr. Papisov has participated in multiple NIH Study Sections and grant review boards established by the Soros Foundation and Harvard University. He is the recipient of three Outstanding Pharmaceutical Paper Awards from the Controlled Release Society (1993, 1995, 2012). He has also received two Best Presentation Awards from the Society of Nuclear Medicine and Molecular Imaging (2016) and from Napa Pain Conference (2016).

Current positions:

  • Scientific Staff, Investigator, Shriners Hospitals for Children — Boston
  • Associate Professor, Harvard Medical School
  • Investigator, Massachusetts General Hospital, Dept. of Radiology and Dept. of Surgery


  • MS, Chemistry, Moscow State University, Moscow, Russia
  • Ph.D., Biology and Biochemistry, Institute of Experimental Cardiology of the National Cardiology Research Center, Moscow, Russia

Scholarly activities: